Conclusion
At the moment, there is not enough research to scientifically substantiate one or another approach to the treatment of patients with hemoblastosis and coronavirus infection. In our experience, we evaluated the effect of complex therapy in patients with hematopoietic malignancies and depression of hematopoiesis with COVID-19, without interrupting chemotherapy. The proposed protocol will presumably reduce the risks of recurrence and refractoriness of the underlying disease. Because of the above, the tactics of managing patients with hematological malignancies in the context of COVID-19 requires further study, which we plan to do in the future.